Parkinson's DiseaseNCT02610634
Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
An observational study of Parkinson's Disease, run by Newcastle-upon-Tyne Hospitals NHS Trust at 1 site in United Kingdom.
Trial summary
Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain. Gait problems, especially veering, may be exacerbated by visuospatial dysfunction which predispose to falls, freezing and festination of gait. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Parkinson's Disease
- How many people
- 100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jul 2013to Feb 2015
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Parkinson's disease participants will be recruited from Movement Disorder Clinics in Newcastle upon-Tyne. Healthy control older adults will be recruited locally within the Newcastle upon Tyne region.
Who may be able to join
- Common to all groups
- Aged ≥50 years
- Able to walk unaided
- Adequate hearing (as evaluated by the whisper test; stand 2m behind participant and whisper a 2 syllable word, participant repeats word) and vision capabilities (as measured using a Snellen chart - 6/18-6/12).
- Stable medication for the past 1 month and anticipated over a period of 6 months
- Group Specific Criteria
Show all 13Show fewer
- Participants with PD:
- Diagnosis of idiopathic PD, as defined by the UK Brain Bank criteria
- Hoehn and Yahr stage I-III
- Stable medication for past 1 month and anticipated over next 6 months or stable Deep Brain Stimulation for at least one month and expected following 6 months
- Score ≥21/30 on Montreal cognitive assessment (MoCA) which is used to classify non-demented PD (PD dementia is <21/30)
- Free from any neurological disorders that may have caused cognitive impairment
- No restriction was made for medication usage and participants on stable doses of medication or treatment were permitted.
Who cannot join
- Common to all groups
- Psychiatric co-morbidity (e.g., major depressive disorder as determined by geriatric depression scale (GDS-15); >10/15)
- Clinical diagnosis of dementia or other severe cognitive impairment (PD = MoCA <21/30, Controls = MoCA <26/30)
- History of stroke, traumatic brain injury or other neurological disorders (other than PD, for that group)
- Acute lower back or lower extremity pain, peripheral neuropathy, rheumatic and orthopaedic diseases
- Unstable medical condition including cardio-vascular instability in the past 6 months
Show all 16Show fewer
- Unable to comply with the testing protocol or currently participating in another interfering research project
- Interfering therapy
- Vision specific Criteria
- Any pupillary diameter disorder; such as significantly non-round pupils, Adies pupil (tonic or dilated pupil), Argyll-Robertson pupil (absence of light reaction), unilateral small pupil
- Neuromotility disorders, such as Nystagmus or other ocular oscillations
- Significant left eye disorders (i.e. squint, twitching, Ptosis [drooping eyelids])
- Known significant visual field deficits; such as hemianopia
- Optic nerve disease
- Optic disc elevation
- Optic disc swelling; such as Papilledema or Papillitis
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Clinical Ageing Research Unit
Newcastle upon Tyne, NE4 5PL
About this study
Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain. Gait problems, especially veering, may be exacerbated by visuospatial dysfunction which predispose to falls, freezing and festination of gait. Visuospatial dysfunction is common in PD and likely involves peripheral features (e.g. contrast sensitivity) as well as central cognitive mechanisms (e.g. attention).
Central neuro-degeneration in PD, PD dementia, and dementia with Lewy Bodies may influence visual function, as impaired visual sampling has been reported in these conditions. Visual sampling is measured via saccadic (fast eye movement) activity, as saccades are the mechanisms through which people orientate and explore the environment. The use of objective devices to reliably measure saccades is important to detect disease related eye movement changes. Emerging visuomotor research has measured visual sampling in PD using devices such as electrooculography and infra-red eye tracking, revealing reduced amplitude, speed and frequency of saccades during various tasks.
Read more
Despite recent increases in visuomotor research it remains unclear how PD influences visual sampling of the environment during gait and the influence of attentional and cognitive deficits. Recent work demonstrated that people with PD sample their environment less frequently than controls, despite a slower gait. Saccadic timing was unchanged in response to environmental cues. Despite this, environmental visual cues (transverse lines on the floor) have been shown to increase the number of fixations made during gait. However the mechanisms of this response remain unclear. Cognition is likely of importance, with response potentially influenced by attentional control.
This observational study aims to examine the influence of cognition on visuomotor control during gait in PD. This aim will be achieved by observation of visual sampling under several environmental challenges (straight walk, doorways, turns, visual cue) and a dual task.
Read the detailed description
This is an observational study of visual sampling during gait under different environmental challenge (straight, doorway, turn and visual cue (transverse lines on the floor)) and dual task. These conditions represent everyday activities/environments which can be difficult for people with PD.
This is not an interventional study as participants are not assigned to any specific interventions by the researchers, or followed up to re-assess outcomes other than for reliability testing of the eye-tracking devices used. The study has been ethically approved (NRES Committee North East - Newcastle \& North Tyneside 1: 13/NE/0128) as an observational study as participants are assigned to pre-defined groups, and have behavioural measures (primarily visual sampling and secondly gait) observed in the gait laboratory under various walking conditions common to everyday environments.
Study Hypotheses
The over-arching hypothesis of this observational study is that visual sampling during gait in PD will be influenced by cognitive impairments. This study hypothesises that saccadic activity will be restricted in PD compared to controls during gait. Dual task and environmental challenge via a doorway, turn or visual cue will influence saccadic activity during gait.
Specific study hypothesises are:
- Cognition will selectively impact on visuomotor control during gait
- Visual sampling strategies during gait will be related to selected domains of cognitive impairment
Secondary questions include:
- Is the Dikablis mobile eye-tracker a reliable means of measuring saccadic activity in PD and healthy controls?
After undergoing screening to confirm eligibility, subjects will be assigned into one of two groups:
- Older adult controls (HC; up to n = 40)
- People with PD (n = 60) Recruitment Participants will be recruited from Movement Disorder Clinics in Newcastle upon-Tyne. Research personnel will be available at clinics as required to invite participants to consider the study. If sufficiently interested, participants will be given a Participant Information Sheet (PIS) and letter concerning the study. The invitation will be followed up by a telephone call during the week to assess willingness to participate. If willing, a mutually convenient time for assessment will be organised, and the invitation to attend will be extended to a carer or spouse. The healthy control group will be recruited via advertisement using posters, which will be placed within neurology and geriatric departments. The advertisement will also be sent via the university email system to staff and students at Newcastle University, the recipients will be advised to pass on the poster to potential interested parties (i.e. family or friends). All participants will be evaluated at the Clinical Ageing Research Unit, Newcastle University, a purpose-build research facility. Testing Protocol Session 1; (up to 150min)
- Initial screening and baseline assessments (45-60min)
- Visual sampling during gait (60-90min) Session 2; (up to 60min)
- 1st Reliability testing (45-60min) (if applicable; for a subgroup of PD and HC participants) Session 3; (up to 60min)
- 2nd Reliability testing (45-60min) (if applicable; for a subgroup of PD and HC participants) Visual sampling during gait (session 1) Participants (n=100) will be assessed in the gait laboratory at the clinical ageing and research unit (CARU), where they will walk under different conditions, for example single task, dual task, through a doorway, whilst turning and with a visual cue (transverse lines on the floor 50cm apart) in place. Visual sampling will be assessed with a Dikablis head-mounted eye tracking and electrooculography (EOG) systems. Gait will be simultaneously assessed using a 3D motion capture system (Vicon), which will be synchronised with the eye tracking systems to provide simultaneous data collection. Infra-red markers will be taped to the body and limbs of the subjects using a small amount of double-sided tape, to allow for motion tracking. The Dikablis will also be taped to the forehead of each participant using a small amount of double sided tape. Reliability testing (subgroup) (session 2 and 3) In order to examine the test re-test reliability of mobile eye-tracking in people with PD and healthy controls, a subgroup of participants (PD and HC; up to n=25) will return for a second (within approx. 1 week) and third visit. They will be asked to repeat some of the walking tasks outlined above and to sit (with chin rest), stand and walk (on a treadmill) while performing several eye movements to visual targets (horizontal and vertical visual angles such as; 5, 10, 15, 20 degrees) in time with an auditory cue (a 60bpm metronome). Participants will return for the third visit approx. 1 week after the second visit and repeat the reliability testing (as above). Sample Size This is an exploratory study and therefore few specific previous examples are available to guide the sample size required. The sample size estimate is based on results from previous work in this research area (PD; n=21) (Galna et al., 2012), other previous similar studies and preliminary pilot work with the Dikabilis mobile eye-tracker, which is a new instrument. Similar studies in this research area have used similar sample sizes (n=2-26), demonstrating that differences between PD and HC groups will been evident. Statistical Analysis Analysis Common to all Studies Statistical analysis will be undertaken using SPSS version 19 or more recent versions (SPPS, Inc. an IBM company). Data checks of all data collected will be carried out independently by two members of the Human Movement Science Team at the Clinical Ageing Research Unit to ensure that data is accurate. All statistical tests will be carried out at the 5% two-sided level of significance. Demographic characteristics and baseline data will be summarized using descriptive statistics, including means, standard deviations, median, minimum, maximum and inter-quartile ranges for continuous or ordinal data and percentages for categorical data. The descriptive statistics will be tabulated and presented graphically for clarity.The assessments recorded at pre-testing will be taken as baseline values. One-sample Kolmogorov-Smirnov tests will be used to check for normally distributed data. Non-normally distributed continuous distributions will be transformed where appropriate to meet the requirements of parametric tests; otherwise equivalent non-parametric tests will be adopted. Further Analysis To analyse visual sampling during gait Pearson's correlations will be used to test the strength and direction of the relationships between clinical, gait and saccadic outcomes. Analysis of variance (ANOVA) will be used to analyse the effect of group (PD, HC), dual task (single task, dual task) and environmental challenge (Straight walk, Door, Turn, Visual cue) on visual sampling during gait. To analyse reliability repeated-measure t-tests, Bland and Altman plots, intra-class correlation coefficients (Model 2, 1) and Pearson correlations (or non-parametric equivalents) will be used to assess bias, agreement and consistency of saccadic outcomes measured with the Dikablis eye-tracker on two separate occasions a week apart.
- Conditions
- Parkinson's Disease
- Keywords
- Parkinson's disease, Older adults, Vision, Cognition, Visual cues, Eye-tracking, Gait, Saccades, Dual task, Visual sampling
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Parkinson's disease | People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21). | |
| Older Adults | Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Sampling Parameter: Saccade Frequency During Gait
Number of fast eye movements made per second observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Secondary outcomes (13)
Gait Parameter: Gait Speed
Measured in meters per second observed when walking recorded via Vicon 3D motion capture. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Gait Parameter: Step Length
Measured in meters recorded via Vicon 3D motion capture. Observed during the following walking conditions; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Gait Parameter: Step Time
Measured in seconds recorded via Vicon 3D motion capture. Observed during the following walking conditions; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins) and one week later in Session 2 for a sub-group (PD and controls n = upto 25) (lasting approx. 60mins)
Gait Parameter: Single Support Time
Measured in seconds recorded via Vicon 3D motion capture. Observed during the following walking conditions; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Gait Parameter: Double Support Time
Measured in seconds recorded via Vicon 3D motion capture. Observed during the following walking conditions; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Number During Gait
Number of fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins) and one week later in Session 2 for a sub-group (PD and controls n = upto 25) (lasting approx. 60mins)
Visual Sampling Parameter: Saccade Velocity During Gait
Velocity (degrees per second) of fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Amplitude During Gait
Distance (degrees) of fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Acceleration During Gait
Acceleration (degrees per second squared) of fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Fixation Number During Gait
Number of pauses (fixations) between fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Fixation Duration During Gait
Duration (ms) of pauses (fixations) between fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Duration During Gait
Duration (ms) of fast eye movements observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Number of Blinks During Gait
Number of blinks observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
Measured: Session 1: observation during gait assessments (lasting approx. 90mins) and one week later in Session 2 for a sub-group (PD and controls n = upto 25) (lasting approx. 60mins)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2015 (estimated)
- Study startJul 2013
- Primary completionFeb 2015
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Newcastle University
- Responsible party
- Sponsor
- Investigators
- Lynn Rochester, PhD, Principal investigator, Newcastle University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02610634
- Sponsor's protocol ID
- 6601
- Other IDs
- CLRN, REC number
- Status last verified
- Sep 2017
- First submitted
- 13 Nov 2015
- Last updated
- 23 Oct 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Lord S, Galna B, Coleman S, Yarnall A, Burn D, Rochester L. Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's disease. Front Aging Neurosci. 2014 Oct 21;6:249. doi: 10.3389/fnagi.2014.00249. eCollection 2014.
PubMed 25374538Galna B, Lord S, Daud D, Archibald N, Burn D, Rochester L. Visual sampling during walking in people with Parkinson's disease and the influence of environment and dual-task. Brain Res. 2012 Sep 14;1473:35-43. doi: 10.1016/j.brainres.2012.07.017. Epub 2012 Jul 20.
PubMed 22824332Stuart S, Alcock L, Galna B, Lord S, Rochester L. The measurement of visual sampling during real-world activity in Parkinson's disease and healthy controls: a structured literature review. J Neurosci Methods. 2014 Jan 30;222:175-88. doi: 10.1016/j.jneumeth.2013.11.018. Epub 2013 Nov 27.
PubMed 24291711Stuart S, Galna B, Lord S, Rochester L, Godfrey A. Quantifying saccades while walking: validity of a novel velocity-based algorithm for mobile eye tracking. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:5739-42. doi: 10.1109/EMBC.2014.6944931.
PubMed 25571299Stuart S, Hickey A, Galna B, Lord S, Rochester L, Godfrey A. iTrack: instrumented mobile electrooculography (EOG) eye-tracking in older adults and Parkinson's disease. Physiol Meas. 2017 Jan;38(1):N16-N31. doi: 10.1088/1361-6579/38/1/N16. Epub 2016 Dec 12.
PubMed 27941232Stuart S, Lord S, Hill E, Rochester L. Gait in Parkinson's disease: A visuo-cognitive challenge. Neurosci Biobehav Rev. 2016 Mar;62:76-88. doi: 10.1016/j.neubiorev.2016.01.002. Epub 2016 Jan 7.
PubMed 26773722Stuart S, Galna B, Lord S, Rochester L. A protocol to examine vision and gait in Parkinson's disease: impact of cognition and response to visual cues. F1000Res. 2015 Nov 30;4:1379. doi: 10.12688/f1000research.7320.2. eCollection 2015.
PubMed 27092242
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
- ClinicalTrials.gov ID
- NCT02610634
- Acronym / sponsor ID
- 6601
- Conditions
- Parkinson's Disease
- Keywords
- Parkinson's disease, Older adults, Vision, Cognition, Visual cues, Eye-tracking, Gait, Saccades
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS TrustUniversity, hospital or other
- Collaborators
- Newcastle University
- Study start
- Jul 2013
- Primary completion
- Feb 2015 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 20 Nov 2015 (estimated)
- Results
- Posted 30 Jan 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain. Gait problems, especially veering, may be exacerbated by visuospatial dysfunction which predispose to falls, freezing and festination of gait. Visuospatial dysfunction is common in PD and likely involves peripheral features (e.g. contrast sensitivity) as well as central cognitive mechanisms (e.g. attention).
Central neuro-degeneration in PD, PD dementia, and dementia with Lewy Bodies may influence visual function, as impaired visual sampling has been reported in these conditions. Visual sampling is measured via saccadic (fast eye movement) activity, as saccades are the mechanisms through which people orientate and explore the environment. The use of objective devices to reliably measure saccades is important to detect disease related eye movement changes. Emerging visuomotor research has measured visual sampling in PD using devices such as electrooculography and infra-red eye tracking, revealing reduced amplitude, speed and frequency of saccades during various tasks.
Despite recent increases in visuomotor research it remains unclear how PD influences visual sampling of the environment during gait and the influence of attentional and cognitive deficits. Recent work demonstrated that people with PD sample their environment less frequently than controls, despite a slower gait. Saccadic timing was unchanged in response to environmental cues. Despite this, environmental visual cues (transverse lines on the floor) have been shown to increase the number of fixations made during gait. However the mechanisms of this response remain unclear. Cognition is likely of importance, with response potentially influenced by attentional control.
This observational study aims to examine the influence of cognition on visuomotor control during gait in PD. This aim will be achieved by observation of visual sampling under several environmental challenges (straight walk, doorways, turns, visual cue) and a dual task.
Detailed description
This is an observational study of visual sampling during gait under different environmental challenge (straight, doorway, turn and visual cue (transverse lines on the floor)) and dual task. These conditions represent everyday activities/environments which can be difficult for people with PD.
This is not an interventional study as participants are not assigned to any specific interventions by the researchers, or followed up to re-assess outcomes other than for reliability testing of the eye-tracking devices used. The study has been ethically approved (NRES Committee North East - Newcastle \& North Tyneside 1: 13/NE/0128) as an observational study as participants are assigned to pre-defined groups, and have behavioural measures (primarily visual sampling and secondly gait) observed in the gait laboratory under various walking conditions common to everyday environments.
Study Hypotheses
The over-arching hypothesis of this observational study is that visual sampling during gait in PD will be influenced by cognitive impairments. This study hypothesises that saccadic activity will be restricted in PD compared to controls during gait. Dual task and environmental challenge via a doorway, turn or visual cue will influence saccadic activity during gait.
Specific study hypothesises are:
- Cognition will selectively impact on visuomotor control during gait
- Visual sampling strategies during gait will be related to selected domains of cognitive impairment
Secondary questions include:
- Is the Dikablis mobile eye-tracker a reliable means of measuring saccadic activity in PD and healthy controls?
After undergoing screening to confirm eligibility, subjects will be assigned into one of two groups:
- Older adult controls (HC; up to n = 40)
- People with PD (n = 60) Recruitment Participants will be recruited from Movement Disorder Clinics in Newcastle upon-Tyne. Research personnel will be available at clinics as required to invite participants to consider the study. If sufficiently interested, participants will be given a Participant Information Sheet (PIS) and letter concerning the study. The invitation will be followed up by a telephone call during the week to assess willingness to participate. If willing, a mutually convenient time for assessment will be organised, and the invitation to attend will be extended to a carer or spouse. The healthy control group will be recruited via advertisement using posters, which will be placed within neurology and geriatric departments. The advertisement will also be sent via the university email system to staff and students at Newcastle University, the recipients will be advised to pass on the poster to potential interested parties (i.e. family or friends). All participants will be evaluated at the Clinical Ageing Research Unit, Newcastle University, a purpose-build research facility. Testing Protocol Session 1; (up to 150min)
- Initial screening and baseline assessments (45-60min)
- Visual sampling during gait (60-90min) Session 2; (up to 60min)
- 1st Reliability testing (45-60min) (if applicable; for a subgroup of PD and HC participants) Session 3; (up to 60min)
- 2nd Reliability testing (45-60min) (if applicable; for a subgroup of PD and HC participants) Visual sampling during gait (session 1) Participants (n=100) will be assessed in the gait laboratory at the clinical ageing and research unit (CARU), where they will walk under different conditions, for example single task, dual task, through a doorway, whilst turning and with a visual cue (transverse lines on the floor 50cm apart) in place. Visual sampling will be assessed with a Dikablis head-mounted eye tracking and electrooculography (EOG) systems. Gait will be simultaneously assessed using a 3D motion capture system (Vicon), which will be synchronised with the eye tracking systems to provide simultaneous data collection. Infra-red markers will be taped to the body and limbs of the subjects using a small amount of double-sided tape, to allow for motion tracking. The Dikablis will also be taped to the forehead of each participant using a small amount of double sided tape. Reliability testing (subgroup) (session 2 and 3) In order to examine the test re-test reliability of mobile eye-tracking in people with PD and healthy controls, a subgroup of participants (PD and HC; up to n=25) will return for a second (within approx. 1 week) and third visit. They will be asked to repeat some of the walking tasks outlined above and to sit (with chin rest), stand and walk (on a treadmill) while performing several eye movements to visual targets (horizontal and vertical visual angles such as; 5, 10, 15, 20 degrees) in time with an auditory cue (a 60bpm metronome). Participants will return for the third visit approx. 1 week after the second visit and repeat the reliability testing (as above). Sample Size This is an exploratory study and therefore few specific previous examples are available to guide the sample size required. The sample size estimate is based on results from previous work in this research area (PD; n=21) (Galna et al., 2012), other previous similar studies and preliminary pilot work with the Dikabilis mobile eye-tracker, which is a new instrument. Similar studies in this research area have used similar sample sizes (n=2-26), demonstrating that differences between PD and HC groups will been evident. Statistical Analysis Analysis Common to all Studies Statistical analysis will be undertaken using SPSS version 19 or more recent versions (SPPS, Inc. an IBM company). Data checks of all data collected will be carried out independently by two members of the Human Movement Science Team at the Clinical Ageing Research Unit to ensure that data is accurate. All statistical tests will be carried out at the 5% two-sided level of significance. Demographic characteristics and baseline data will be summarized using descriptive statistics, including means, standard deviations, median, minimum, maximum and inter-quartile ranges for continuous or ordinal data and percentages for categorical data. The descriptive statistics will be tabulated and presented graphically for clarity.The assessments recorded at pre-testing will be taken as baseline values. One-sample Kolmogorov-Smirnov tests will be used to check for normally distributed data. Non-normally distributed continuous distributions will be transformed where appropriate to meet the requirements of parametric tests; otherwise equivalent non-parametric tests will be adopted. Further Analysis To analyse visual sampling during gait Pearson's correlations will be used to test the strength and direction of the relationships between clinical, gait and saccadic outcomes. Analysis of variance (ANOVA) will be used to analyse the effect of group (PD, HC), dual task (single task, dual task) and environmental challenge (Straight walk, Door, Turn, Visual cue) on visual sampling during gait. To analyse reliability repeated-measure t-tests, Bland and Altman plots, intra-class correlation coefficients (Model 2, 1) and Pearson correlations (or non-parametric equivalents) will be used to assess bias, agreement and consistency of saccadic outcomes measured with the Dikablis eye-tracker on two separate occasions a week apart.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Parkinson's disease | – | –People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21). |
| Older Adults | – | –Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26). |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Parkinson's disease participants will be recruited from Movement Disorder Clinics in Newcastle upon-Tyne. Healthy control older adults will be recruited locally within the Newcastle upon Tyne region.
Key inclusion criteria (13 listed)
- Common to all groups
- Aged ≥50 years
- Able to walk unaided
- Adequate hearing (as evaluated by the whisper test; stand 2m behind participant and whisper a 2 syllable word, participant repeats word) and vision capabilities (as measured using a Snellen chart - 6/18-6/12).
- Stable medication for the past 1 month and anticipated over a period of 6 months
Key exclusion criteria (16 listed)
- Common to all groups
- Psychiatric co-morbidity (e.g., major depressive disorder as determined by geriatric depression scale (GDS-15); >10/15)
- Clinical diagnosis of dementia or other severe cognitive impairment (PD = MoCA <21/30, Controls = MoCA <26/30)
- History of stroke, traumatic brain injury or other neurological disorders (other than PD, for that group)
- Acute lower back or lower extremity pain, peripheral neuropathy, rheumatic and orthopaedic diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Visual Sampling Parameter: Saccade Frequency During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Number of fast eye movements made per second observed when walking, measured via EOG and Dikablis mobile eye-tracker. Walking conditions include; single task, dual task, through a doorway, whilst turning and with a visual cue in place.
13 secondary outcomes
Gait Parameter: Gait Speed
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Gait Parameter: Step Length
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Gait Parameter: Step Time
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins) and one week later in Session 2 for a sub-group (PD and controls n = upto 25) (lasting approx. 60mins)
Gait Parameter: Single Support Time
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Gait Parameter: Double Support Time
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Number During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins) and one week later in Session 2 for a sub-group (PD and controls n = upto 25) (lasting approx. 60mins)
Visual Sampling Parameter: Saccade Velocity During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Amplitude During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Acceleration During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Fixation Number During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Fixation Duration During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Saccade Duration During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins)
Visual Sampling Parameter: Number of Blinks During Gait
Time frame: Session 1: observation during gait assessments (lasting approx. 90mins) and one week later in Session 2 for a sub-group (PD and controls n = upto 25) (lasting approx. 60mins)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 25374538Lord S, Galna B, Coleman S, Yarnall A, Burn D, Rochester L. Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's disease. Front Aging Neurosci. 2014 Oct 21;6:249. doi: 10.3389/fnagi.2014.00249. eCollection 2014.
- Background: PubMed 22824332Galna B, Lord S, Daud D, Archibald N, Burn D, Rochester L. Visual sampling during walking in people with Parkinson's disease and the influence of environment and dual-task. Brain Res. 2012 Sep 14;1473:35-43. doi: 10.1016/j.brainres.2012.07.017. Epub 2012 Jul 20.
- Results publication: PubMed 24291711Stuart S, Alcock L, Galna B, Lord S, Rochester L. The measurement of visual sampling during real-world activity in Parkinson's disease and healthy controls: a structured literature review. J Neurosci Methods. 2014 Jan 30;222:175-88. doi: 10.1016/j.jneumeth.2013.11.018. Epub 2013 Nov 27.
- Results publication: PubMed 25571299Stuart S, Galna B, Lord S, Rochester L, Godfrey A. Quantifying saccades while walking: validity of a novel velocity-based algorithm for mobile eye tracking. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:5739-42. doi: 10.1109/EMBC.2014.6944931.
- Results publication: PubMed 27941232Stuart S, Hickey A, Galna B, Lord S, Rochester L, Godfrey A. iTrack: instrumented mobile electrooculography (EOG) eye-tracking in older adults and Parkinson's disease. Physiol Meas. 2017 Jan;38(1):N16-N31. doi: 10.1088/1361-6579/38/1/N16. Epub 2016 Dec 12.
- Results publication: PubMed 26773722Stuart S, Lord S, Hill E, Rochester L. Gait in Parkinson's disease: A visuo-cognitive challenge. Neurosci Biobehav Rev. 2016 Mar;62:76-88. doi: 10.1016/j.neubiorev.2016.01.002. Epub 2016 Jan 7.
- Results publication: PubMed 27092242Stuart S, Galna B, Lord S, Rochester L. A protocol to examine vision and gait in Parkinson's disease: impact of cognition and response to visual cues. F1000Res. 2015 Nov 30;4:1379. doi: 10.12688/f1000research.7320.2. eCollection 2015.
Related trials for Parkinson's Disease
Recruiting
Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease
Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
Parkinson&Amp;#39;s Disease
Not yet recruiting
Cognitive-Motor Training for Gait Adaptability in Parkinson Disease
Parkinson Disease
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
RecruitingPhase 2/3
A Study of Buntanetap in Participants With PD
Parkinson's Disease (PD), Deep Brain Stimulation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lynn Rochester, PhD principal investigator
Newcastle University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson's Disease, run by Newcastle-upon-Tyne Hospitals NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 Jan 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Sampling Parameter: Saccade Frequency During Gait (time frame: Session 1: observation during gait assessments (lasting approx. 90mins)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02610634, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2017.